{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T01:56:04Z","timestamp":1676771764293},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T00:00:00Z","timestamp":1205193600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s00259-008-0727-z","type":"journal-article","created":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T07:17:47Z","timestamp":1205133467000},"page":"1236-1239","source":"Crossref","is-referenced-by-count":7,"title":["Consolidation radioimmunotherapy of follicular lymphoma: a step towards cure?"],"prefix":"10.1007","volume":"35","author":[{"given":"Jean-Fran\u00e7ois","family":"Chatal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Barbet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,11]]},"reference":[{"key":"727_CR1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ijc.2910410819","volume":"3","author":"SJ DeNardo","year":"1988","unstructured":"DeNardo SJ, DeNardo GL, O\u2019Grady LF, Hu E, Svtsma VM, Mills SL, et al. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl 1988;3:96\u2013101.","journal-title":"Int J Cancer Suppl"},{"key":"727_CR2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.1989.7.8.1027","volume":"7","author":"OW Press","year":"1989","unstructured":"Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, et al. Treatment of refractory non-Hodgkin\u2019s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027\u201338.","journal-title":"J Clin Oncol"},{"key":"727_CR3","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2967\/jnumed.107.043489","volume":"48","author":"HA Jacene","year":"2007","unstructured":"Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48:1767\u201376.","journal-title":"J Nucl Med."},{"key":"727_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/cbr.2006.21.1","volume":"21","author":"JF Chatal","year":"2006","unstructured":"Chatal JF. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin\u2019s lymphoma: the European perspective. Cancer Biother Radiopharm 2006;21:1\u20134.","journal-title":"Cancer Biother Radiopharm"},{"key":"727_CR5","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002;20:2453\u201363.","journal-title":"J Clin Oncol"},{"key":"727_CR6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","volume":"47","author":"C Emmanouilides","year":"2006","unstructured":"Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 2006;47:629\u20133.","journal-title":"Leuk Lymphoma"},{"key":"727_CR7","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","volume":"102","author":"OW Press","year":"2003","unstructured":"Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102:1606\u201312.","journal-title":"Blood"},{"key":"727_CR8","doi-asserted-by":"crossref","first-page":"560a","DOI":"10.1200\/jco.2004.22.14_suppl.8500","volume":"22","author":"B Link","year":"2004","unstructured":"Link B, Kaminski MS, Coleman M, Leonard JP. Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol 2004;22:560a. (suppl, abstr 6520).","journal-title":"J Clin Oncol"},{"key":"727_CR9","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","volume":"23","author":"JP Leonard","year":"2005","unstructured":"Leonard JP, Coleman M, Kostakoglu L, Chadbum A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696\u2013704.","journal-title":"J Clin Oncol"},{"key":"727_CR10","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","volume":"24","author":"OW Press","year":"2006","unstructured":"Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143\u201349.","journal-title":"J Clin Oncol"},{"key":"727_CR11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/jco.2005.23.16_suppl.6577","volume":"23","author":"DL Shipley","year":"2005","unstructured":"Shipley DL, Greco FA, Spigel DR, et al. Rituximab with short duration chemotherapy followed by Y-90 ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2005;23:579. (suppl I; abstr 6577).","journal-title":"J Clin Oncol"},{"key":"727_CR12","doi-asserted-by":"crossref","first-page":"198a","DOI":"10.1182\/blood.V110.11.198.198","volume":"110","author":"A Hagenbeck","year":"2007","unstructured":"Hagenbeck A, Bischof-Delaloye A, Radford JA, Rohatiner A, Salles G, Van Hoof A, et al. 90Y-ibritumomab tiuxetan (Zevalin\u00ae) consolidation of first remission in advanced stage follicular non-Hodgkin\u2019s lymphoma: first results of the international randomized phase 3 first-line indolent trial (FIT) in 414 patients. Blood 2007;110:198a. (suppl; abstr 643).","journal-title":"Blood"},{"key":"727_CR13","doi-asserted-by":"crossref","unstructured":"Jurczak W, Giza A, Zimowska-Curylo D, Hubalewska-Dydejczk A, Sowa-Staszczak A, Knopinska-Posluszny W, et al. 90Y-Zevalin\u00ae (90Y-ibritumomab tiuxetan) radioimmunotherapy (RIT) consolidation in mantle cell lymphoma (MCL) patients, not eligible for intensive therapy protocols. Blood 2007;110:(suppl; abstr 4497).","DOI":"10.1182\/blood.V110.11.4497.4497"},{"key":"727_CR14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.10894","volume":"92","author":"MHJ Oers Van","year":"2007","unstructured":"Van Oers MHJ. Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica 2007;92:826\u201333.","journal-title":"Haematologica"},{"key":"727_CR15","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/10428190701422059","volume":"48","author":"S Bishu","year":"2007","unstructured":"Bishu S, Quigley JM, Bishu SR, Olsasky SM, Stem RA, Shostrom VK, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 2007;48:1548\u201355.","journal-title":"Leuk Lymphoma"},{"key":"727_CR16","first-page":"2000","volume":"44","author":"RM Sharkey","year":"2003","unstructured":"Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, et al. Radioimmunotherapy of non-Hodgkin\u2019s lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 2003;44:2000\u201318.","journal-title":"J Nucl Med"},{"key":"727_CR17","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1080\/10428190701573273","volume":"48","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Nagler A. Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma. Leuk Lymphoma 2007;48:2110\u201320.","journal-title":"Leuk Lymphoma"},{"key":"727_CR18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","volume":"26","author":"A Krishnan","year":"2008","unstructured":"Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol 2008;26:90\u20135.","journal-title":"J Clin Oncol"},{"key":"727_CR19","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1200\/JCO.2005.18.622","volume":"23","author":"T Liersch","year":"2005","unstructured":"Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23:6763\u201370.","journal-title":"J Clin Oncol"},{"key":"727_CR20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.2005.03.8471","volume":"24","author":"DM Goldenberg","year":"2006","unstructured":"Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823\u201334.","journal-title":"J Clin Oncol"},{"key":"727_CR21","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2005.04.4917","volume":"24","author":"JF Chatal","year":"2006","unstructured":"Chatal JF, Campion L, Kraeber-Bod\u00e9r\u00e9 F, Bardet S, Vuillez JP, Charbonnel B, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin oncol 2006;24:1705\u201311.","journal-title":"J Clin oncol"},{"key":"727_CR22","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/nm1322","volume":"11","author":"RM Sharkey","year":"2005","unstructured":"Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, Mcbride WJ, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250\u201355.","journal-title":"Nat Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-008-0727-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-008-0727-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-008-0727-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T21:30:41Z","timestamp":1588455041000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-008-0727-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,11]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1007\/s00259-008-0727-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,11]]}}}